

# World Journal of *Clinical Cases*

*World J Clin Cases* 2023 July 6; 11(19): 4458-4733



## Contents

Thrice Monthly Volume 11 Number 19 July 6, 2023

### REVIEW

- 4458** Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review  
*Singh SV, Ganguly R, Jaiswal K, Yadav AK, Kumar R, Pandey AK*
- 4477** Diffusion tensor imaging in the courtroom: Distinction between scientific specificity and legally admissible evidence  
*van Velkinburgh JC, Herbst MD, Casper SM*

### MINIREVIEWS

- 4498** Inequity in the global distribution of monkeypox vaccines  
*Tovani-Palone MR, Doshi N, Pedersini P*
- 4504** Long-term effectiveness, outcomes and complications of bariatric surgery  
*Gulinac M, Miteva DG, Peshevska-Sekulovska M, Novakov IP, Antovic S, Peruhova M, Snegarova V, Kabakchieva P, Assyov Y, Vasilev G, Sekulovski M, Lazova S, Tomov L, Velikova T*

### ORIGINAL ARTICLE

#### Retrospective Cohort Study

- 4513** Age, blood tests and comorbidities and AIMS65 risk scores outperform Glasgow-Blatchford and pre-endoscopic Rockall score in patients with upper gastrointestinal bleeding  
*Morarasu BC, Sorodoc V, Haisan A, Morarasu S, Bologa C, Haliga RE, Lionte C, Marciuc EA, Elsiddig M, Cimpoesu D, Dimofte GM, Sorodoc L*

#### Retrospective Study

- 4531** Application of cross-migration theory in limb rehabilitation of stroke patients with hemiplegia  
*Lu YH, Fu Y, Shu J, Yan LY, Shen HJ*
- 4544** Analysis of characteristic features in ultrasound diagnosis of fetal limb body wall complex during 11-13<sup>+</sup> weeks  
*Ye CH, Li S, Ling L*
- 4553** Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer  
*Li YJ, Tang DX, Yan HT, Yang B, Yang Z, Long FX*
- 4567** Assessment of functional prognosis of anterior cruciate ligament reconstruction in athletes based on a body shape index  
*Wang YJ, Zhang JC, Zhang YZ, Liu YH*

**EVIDENCE-BASED MEDICINE**

- 4579** Network pharmacology and molecular docking to explore Polygoni Cuspidati Rhizoma et Radix treatment for acute lung injury

*Zheng JL, Wang X, Song Z, Zhou P, Zhang GJ, Diao JJ, Han CE, Jia GY, Zhou X, Zhang BQ*

**ORIGINAL ARTICLE****Randomized Controlled Trial**

- 4601** Ulinastatin in the treatment of severe acute pancreatitis: A single-center randomized controlled trial

*Wang SQ, Jiao W, Zhang J, Zhang JF, Tao YN, Jiang Q, Yu F*

- 4612** Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial

*da Ponte Neto AM, Clemente ACO, Rosa PW, Ribeiro IB, Funari MP, Nunes GC, Moreira L, Sparvoli LG, Cortez R, Taddei CR, Mancini MC, de Moura EGH*

**SYSTEMATIC REVIEWS**

- 4625** Combined medial patellofemoral ligament and medial patellotibial ligament reconstruction in recurrent patellar instability: A systematic review and meta-analysis

*Abbaszadeh A, Saeedi M, Hoveidaei AH, Dadgostar H, Razi S, Razi M*

**CASE REPORT**

- 4635** Unique Roberts syndrome with bilateral congenital glaucoma: A case report

*Almulhim A, Almoallem B, Alsirhy E, Osman EA*

- 4640** CK5/6-positive, P63-positive lymphoepithelioma-like hepatocellular carcinoma: A case report and literature review

*Tang HT, Lin W, Zhang WQ, Qian JL, Li K, He K*

- 4648** Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports

*Yang L, Xu X, Wang L, Zeng KB, Wang XF*

- 4655** CDKN1C gene mutation causing familial Silver-Russell syndrome: A case report and review of literature

*Li J, Chen LN, He HL*

- 4664** Hypothetical hypoxia-driven rapid disease progression in hepatocellular carcinoma post transarterial chemoembolization: A case report

*Yeo KF, Ker A, Kao PE, Wang CC*

- 4670** Metastatic colon cancer treated using traditional Chinese medicine combined with chemotherapy: A case report

*Deng CG, Tang MY, Pan X, Liu ZH*

- 4677** Rare cause of cerebral venous sinus thrombosis: Spontaneous intracranial hypotension syndrome: A case report

*Huang P*

- 4684** Integrated Chinese and Western medicine in the treatment of a patient with podocyte infolding glomerulopathy: A case report  
*Chang MY, Zhang Y, Li MX, Xuan F*
- 4692** Morbihan disease misdiagnosed as senile blepharoptosis and successfully treated with short-term minocycline and ketotifen: A case report  
*Na J, Wu Y*
- 4698** With two episodes of right retromandibular angle subcutaneous emphysema during right upper molar crown preparation: A case report  
*Bai YP, Sha JJ, Chai CC, Sun HP*
- 4707** Poststroke rehabilitation using repetitive transcranial magnetic stimulation during pregnancy: A case report  
*Jo J, Kim H*
- 4713** Tuberculosis-induced aplastic crisis and atypical lymphocyte expansion in advanced myelodysplastic syndrome: A case report and review of literature  
*Sun XY, Yang XD, Xu J, Xiu NN, Ju B, Zhao XC*
- 4723** Posterior reversible encephalopathy syndrome following uneventful clipping of an unruptured intracranial aneurysm: A case report  
*Hwang J, Cho WH, Cha SH, Ko JK*

**ACADEMIC WRITING**

- 4729** Revitalizing case reports: Standardized guidelines and mentorship  
*Jeyaraman M, Ramasubramanian S, Jeyaraman N, Nallakumarasamy A, Sharma S*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Miroslav Vujasinovic, MD, PhD, Associate Professor, Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm 14186, Sweden. mvujas@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Si Zhao; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

July 6, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Randomized Controlled Trial

## Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial

Alberto Machado da Ponte Neto, Aniele Cristine Ott Clemente, Paula Waki Rosa, Igor Braga Ribeiro, Mateus Pereira Funari, Gabriel Cairo Nunes, Luana Moreira, Luiz Gustavo Sparvoli, Ramon Cortez, Carla Romano Taddei, Márcio C Mancini, Eduardo Guimarães Hourneaux de Moura

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Farhat H, Qatar; Sun SY, China

**Received:** January 10, 2023

**Peer-review started:** January 10, 2023

**First decision:** January 21, 2023

**Revised:** January 26, 2023

**Accepted:** May 4, 2023

**Article in press:** May 4, 2023

**Published online:** July 6, 2023



**Alberto Machado da Ponte Neto, Igor Braga Ribeiro, Mateus Pereira Funari, Gabriel Cairo Nunes, Eduardo Guimarães Hourneaux de Moura,** Department of Gastroenterology, Faculdade de Medicina, Universidade de São Paulo, Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, São Paulo 05403-010, SP, Brazil

**Aniele Cristine Ott Clemente, Paula Waki Rosa, Márcio C Mancini,** Department of Endocrinology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo 05403-010, SP, Brazil

**Luana Moreira, Luiz Gustavo Sparvoli, Ramon Cortez, Carla Romano Taddei,** Department of Clinical and Toxicology Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05403-010, SP, Brazil

**Carla Romano Taddei,** School of Arts, Science and Humanities, University of São Paulo, São Paulo 05403-010, SP, Brazil

**Corresponding author:** Igor Braga Ribeiro, MD, PhD, Associate Research Scientist, Attending Doctor, Doctor, Research Scientist, Department of Gastroenterology, Faculdade de Medicina, Universidade de São Paulo, Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, Av. Dr Enéas de Carvalho Aguiar, 225, 6o andar, bloco 3, Cerqueira Cesar, São Paulo 05403-010, SP, Brazil. [igorbraga1@gmail.com](mailto:igorbraga1@gmail.com)

### Abstract

#### BACKGROUND

Metabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.

#### AIM

To evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.

#### METHODS

This was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.

## RESULTS

There was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.

## CONCLUSION

There were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.

**Key Words:** Fecal microbiota transplantation; Metabolic syndrome; Obesity; Endoscopy; Diabetes mellitus; Endocrinology

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The prevalence of metabolic syndrome is a pandemic that goes hand in hand with obesity and diabetes, affecting almost half of the world's population. Therapeutic approaches targeting dysbiosis and manipulation of the gut microbiome have become options and are being tested. Such approaches include the use of prebiotics, probiotics, synbiotics, antibiotics and fecal microbiota transplantation (FMT). It is known that FMT can alter the intestinal microbiota and increase its diversity, resulting in a microbiome that can help decrease body fat and increase insulin sensitivity, as well as facilitate the treatment of metabolic syndrome and obesity. This was a randomized controlled trial comparing FMT and a sham procedure in patients with the metabolic syndrome.

**Citation:** da Ponte Neto AM, Clemente ACO, Rosa PW, Ribeiro IB, Funari MP, Nunes GC, Moreira L, Sparvoli LG, Cortez R, Taddei CR, Mancini MC, de Moura EGH. Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial. *World J Clin Cases* 2023; 11(19): 4612-4624

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i19/4612.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v11.i19.4612>

## INTRODUCTION

The prevalence of metabolic syndrome parallels that of obesity and diabetes—up to 45% of the population worldwide—and is expected to rise as a consequence of increasing longevity and unhealthy lifestyles[1,2]. Obesity has become one of the most important public health problems in the United States and in many other resource-rich countries, as well as in transitional economies. The increase in the prevalence of obesity has resulted in increases in the incidence of associated diseases such as diabetes and hypertension[3,4].

Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease [5,6]. Individuals in whom the metabolic risk factors for type two diabetes coexist with those for cardiovascular disease are classified as having metabolic syndrome[7].

There are many treatment modalities for obesity and metabolic syndrome. However, optimal management is still a challenge because multiple factors are involved in its physiopathology, such as genetic predisposition, sedentary lifestyle, and a specific distribution of body fat[8,9]. Therapeutic approaches targeting dysbiosis and manipulation of the gut microbiome have recently been developed. Such approaches include the use of prebiotics, probiotics, synbiotics, antibiotics, and fecal microbiota



transplantation (FMT). It is known that FMT can change the gut microbiota and increase its diversity, resulting in a microbiome that could help decrease body fat and increase insulin sensitivity, as well as facilitating the treatment of metabolic syndrome and obesity. The gut microbiota is composed of trillions of microorganisms that can influence the human organism by various mechanisms, having been associated with many diseases and conditions, including obesity and metabolic syndrome[10-14].

The aim of this study was to evaluate the outcomes of FMT in patients with metabolic syndrome. To that end, we performed a randomized placebo-controlled clinical trial.

## MATERIALS AND METHODS

### Study design

This was a randomized, single-blind, placebo-controlled clinical trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected patients who had been diagnosed with metabolic syndrome according to the 2006 International Diabetes Federation criteria[2]. Additional inclusion criteria were being female, being between 18 and 70 years of age, and having a body mass index (BMI) of 30–40 kg/m<sup>2</sup>. Patients who had previously undergone gastrointestinal surgery were excluded, as were those with immunodeficiency, those who had previously undergone treatment for obesity, and those who had used any weight loss medication, antibiotics, or probiotics within the last three months. The primary end point was a change in the gut microbiota.

After an initial screening for the characteristics of metabolic syndrome, the patients were referred for consultations with a nutritionist and an endocrinologist. Anthropometric, bioimpedance, and biochemical data were analyzed.

The study was approved by the Research Ethics Committee of the *Hospital das Clínicas* (CAAE: 62319916.9.0000.0068) operated by the University of São Paulo School of Medicine, in the city of São Paulo, Brazil. All participating patients provided written informed consent.

### Study population

Female patients with class I or II obesity were recruited following an advertisement at the entrance of the Hospital das Clínicas. We included 32 female patients (age range, 20–69 years) with class II obesity (BMI 30–40 kg/m<sup>2</sup>) and metabolic syndrome. Metabolic syndrome was defined as a fasting glucose level > 100 mg/dL or use of antidiabetic medications or insulin, plus at least two of the following criteria: triglycerides ≥ 150 mg/dL; high-density lipoprotein cholesterol < 50 mg/dL (the standard for women); blood pressure ≥ 130/85 mmHg or use of antihypertensive medication; and abdominal obesity, defined as a waist circumference ≥ 80 cm (the standard for women).

We chose to use a single feces donor, in an attempt to maintain the same bacterial diversity for all recipients, despite the fact that not all of the donations were made on the same day. To screen the donor, we used the protocol devised by van Nood *et al*[15]. The donor (a 30-year-old female) was a volunteer and was initially screened with a questionnaire on communicable diseases. Stool and blood samples were collected. The stool sample was screened for parasites, *Clostridium difficile*, and enteropathogenic bacteria. The blood sample was screened for the following: antibodies to human immunodeficiency virus; human T-cell lymphotropic virus types I and II; hepatitis A, B, and C; cytomegalovirus; Epstein–Barr virus; *Treponema pallidum*; *Strongyloides stercoralis*; and *Entamoeba histolytica*. The screening was repeated every 4 mo during the 1-year donation period. Immediately prior to each donation, another questionnaire was used in order to identify any recent illness[15].

### Sample collection

On the day of the procedure, a stool sample was collected from each patient. In most cases, the samples were collected from a spontaneous evacuation by the patient prior to the procedure or by digital rectal extraction after the patient had been sedated. In one patient, it was necessary to perform proctoscopy to obtain the stool sample, which was captured with a snare. After the stool samples had been labeled, they were stored at –80°C.

### Preparation of microbiota solution

On the day of donation, the microbiota solution was prepared by diluting 200 g of donor feces in 500 mL of sterile saline. The solution was stirred, after which the supernatant was strained and transferred to a sterile bottle[15]. Immediately after preparation, the microbiota solution was transported from the laboratory to the endoscopy center.

### Procedure

The 32 patients were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. All procedures were performed at the endoscopy center of the *Hospital das Clínicas*.



All of the patients underwent upper gastrointestinal endoscopy under sedation. Infusions were performed with an oscope, which was advanced past the ligament of Treitz and released 200 mL of the microbiota or saline solution. In the FMT patients, the solution was infused within 4 h after the feces had been collected from the donor.

### Follow-up

The patients underwent follow-up for one year after the procedure, during which time they had additional consultations with a nutritionist and an endocrinologist: at six weeks, six months, and one year. At each visit, anthropometric parameters, medication use, antibiotic use, and patient complaints were evaluated. Stool samples collected at each time point (baseline, six weeks, six months, and one year) were analyzed.

After the procedures, the patients were required to adhere to a standardized diabetic diet (1000 calories/day) and were instructed to keep a food diary for a period of one year. They were also instructed to use no probiotics and to inform the research team if they needed to use antibiotics.

### DNA extraction and paired-end sequencing

A 200-mg aliquot of feces from each patient was analyzed with the QiaAmp DNA Stool Mini Kit (QIAGEN, Hilden, Germany), in accordance with the manufacturer's protocol. The V4 region of the 16S rRNA gene was amplified using the primers V4 F (TCGTCGGCAG CCACTGATGTGTATAA-GAGACAGGTGCCAGCMGCC GCGGTAA) and V4 R (GTCTCGTGGGCTCGGAGATGTGTATAA-GAGACAGGGACTACHVGGGTWTCTAAT)[16]. Amplification was performed in two steps with a custom Illumina preparation protocol (Illumina, San Diego, CA, USA). The samples were pooled and loaded into an Illumina MiSeq reagent cartridge (Illumina, San Diego, CA) for paired-end, 500-cycle sequencing at a final concentration of 12 pM. The library was clustered at a density of approximately 820 K/mm<sup>2</sup>. Image analysis, base calling, and data quality assessment were performed on the MiSeq platform. A DNA-free negative control was used, and polymerase-chain-reaction steps were performed. On a gel, no visible amplification signal was observed for the no-template control, indicating that bacterial contamination was minimal.

**Bioinformatic analysis:** The raw reads were demultiplexed and analyzed using QIIME software, version 1.9[17]. The software was used in order to remove barcodes and primer sequences, as well as to extract chimeric artifacts, align sequences, construct distance matrices, define operational taxonomic units (for phylogenetic tree construction), calculate diversity indices, and test hypotheses. After removing the barcodes and primers, we filtered the sequences, discarding the reads that were smaller than approximately 400 bp. We then checked for chimeras, using USEARCH[17], and excluded the sequences identified as chimeric. The sequences of the remaining libraries were grouped into operational taxonomic units, based on 97% similarity to sequences in the SILVA database, version 128 [18]. The relative abundance of the bacteria was determined in relation to the main phyla and genera that appeared in at least 1% of the total found in both groups.

The alpha and beta diversity indices were calculated for each library. To calculate the alpha diversity, we used the Chao1 richness estimate[19], together with the Shannon and Simpson diversity indices[20, 21]. To calculate the beta diversity, we constructed a principal coordinate analysis plot based on the weighted and unweighted UniFrac distance matrices[22,23]. Nucleic acid sequences are available at the Sequence Read Archive (accession number, PRJNA766355).

### Statistical analysis

Initially, all variables were analyzed descriptively. For quantitative variables, we observed the minimum and maximum values, as well as calculating means, standard deviations, and quartiles. For qualitative variables, we calculated absolute and relative frequencies.

To compare means between the two groups, we used Student's t-tests[24]. When the assumption of normality of the data was rejected, we used the nonparametric Mann-Whitney test[24]. To compare the groups over time, we used the nonparametric Mann-Whitney, Wilcoxon, and Friedman tests with Bonferroni correction[24].

The generalized linear model was used in order to compare the two groups, in relation to the clinical data, through linear and ordinal logistic regression. This model was also used in order to evaluate the effect of the independent variable (FMT) on the dependent variables—alpha diversity indices (with gamma distribution) and relative abundance of bacterial phyla and genera (with linear distribution). To detect between-group differences in beta diversity, we used permutational multivariate analysis of variance, with the adonis function for Bray-Curtis distances. For each variable, 999 permutations were used.

To study the correlations between the preprocedural and postprocedural periods, we employed Spearman's correlation coefficient[24]. All statistical analyses were performed with the SPSS Statistics software package, version 17.0 (SPSS Inc., Chicago, IL, USA). The significance level adopted for all tests was 5%.

## RESULTS

### Participants

We included 32 patients with metabolic syndrome and one feces donor. Of the 32 patients evaluated, four did not complete the study: two withdrew after randomization; one became pregnant during follow-up; and one withdrew during follow-up. Therefore, the final sample comprised 28 patients: 15 in the FMT group and 13 in the placebo group as shown in the CONSORT flow diagram in the [Supplementary material](#).

### General characteristics and clinical data

When we evaluated all 32 patients at baseline, there were no statistical differences between the two groups in terms of the mean age ( $55.20 \pm 10.22$  years *vs*  $53.62 \pm 13.09$  years,  $P = 0.722$ ), body weight ( $94.12 \pm 8.27$  kg *vs*  $89.29 \pm 5.70$  kg,  $P = 0.867$ ), or BMI ( $36.69 \pm 2.94$  kg/m<sup>2</sup> *vs*  $35.74 \pm 2.22$  kg/m<sup>2</sup>,  $P = 0.719$ ). [Table 1](#) shows the change in body weight over the course of the study, by group, among the 28 patients who completed the study. Overall, no significant differences were found between the two groups regarding the general and clinical characteristics at the time of sample collection.

No serious adverse events were reported in either group. We also observed no statistical differences between the two groups in terms of biochemical parameters (*e.g.*, hematology, glucose, renal function, and liver chemistry), lean mass, or the percentage of body fat.

### Clinical follow-up

At 6 wk, 6 mo, and one year after the procedures, there were no statistical differences between the FMT and placebo groups for any of the following: body weight; BMI; waist circumference; hip circumference; fasting glucose; insulin; glycated hemoglobin ([Table 2](#)); the insulin resistance profile; the respiratory compensation point; and the lipid profile.

### Microbiome analysis

In both groups, the predominant phyla were Firmicutes and Bacteroidetes ([Figure 1](#)). At 6 wk after the procedures, the relative abundance of Firmicutes was higher in the placebo group than in the FMT group ([Figure 1A](#) and [Supplementary Table 1](#)). Over the course of the study period, the abundance of Firmicutes in the FMT group increased, whereas that of Bacteroidetes decreased in that group, resulting in the Firmicutes/Bacteroidetes ratio being higher in the FMT group than in the placebo group. In both groups, the most abundant genera were *Bacteroides*, *Prevotella*, *Ruminococcaceae* UCG-002, and *Megasphaera* ([Figure 1B](#) and [Supplementary Table 2](#)). Although there were no significant differences in the abundances of genera and phyla between the groups and among the time points, there was a marked increase in *Ruminococcus* 2 and *Phascolarctobacterium* in the placebo group, as well as a decrease in *Bacteroides* in the FMT group. Over the course of the study, the abundances of *Prevotella*, *Ruminococcaceae* UCG-002, and *Faecalibacterium* were higher in the FMT group than in the placebo group.

### Alpha and beta diversity

There were no significant differences between the FMT and placebo groups in terms of the alpha diversity ([Figure 2](#)). However, we observed a significant negative correlation between the Shannon diversity index and the percentage of body fat in both groups. We also found that the Chao1 richness estimate showed a significant negative correlation with fat mass, as did the Shannon and Simpson diversity indices.

The beta diversity of the microbial community showed significant differences between the FMT and placebo groups over the course of the study ([Figure 3](#)): At baseline ( $F = 0.83294$ ,  $R^2 = 0.033542$ ,  $P = 0.603$ ); at 6 wk after the procedures ( $F = 1.9699$ ,  $R^2 = 0.070431$ ,  $P = 0.039$ ); and at 1 year after the procedures ( $F = 3.0656$ ,  $R^2 = 0.15278$ ,  $P < 0.003$ ).

## DISCUSSION

The gut microbiota has been shown to play a role in a number of diseases, including inflammatory bowel disease[25-27], pseudomembranous colitis[28], primary sclerosing cholangitis[29], and cardiovascular disease. The gut microbiota also interacts with obesity, metabolic syndrome, and insulin resistance[30] which have common risk factors and are highly correlated.

The gut microbiota appears to be an important factor in the development of obesity and metabolic syndrome, FMT therefore being a possible treatment modality. Controlled studies have shown that FMT alters the gut microbiota of rats and reduces their weight, indicating that the microbiota is directly related to nutrient absorption capacity[12].

In one randomized controlled study of FMT, involving male patients with metabolic syndrome[31], the glycemic profile at six weeks after FMT was found to be better in the patients who received microbiota (from lean individuals) than in those who received autologous microbiota. In another

**Table 1 Body weight over the course of the study, by group**

Group	N	Mean	SD	Range	Median	IQR
FMT ( <i>n</i> = 15)						
Baseline	14	94.18	7.95	82.00–110.00	93.50	87.75–100.38
6 wk	14	93.86	9.94	82.00–114.00	93.00	85.00–100.50
6 mo	14	94.21	11.24	78.00–115.00	94.00	84.50–99.25
1 yr	14	95.79	11.05	81.00–116.00	95.00	86.50–102.25
Placebo ( <i>n</i> = 13)						
Baseline	12	91.28	10.60	82.00–120.00	89.50	83.25–94.50
6 wk	12	89.79	9.53	80.50–112.00	86.50	82.25–96.75
6 mo	12	89.58	10.87	77.00–115.00	88.50	81.25–93.75
1 yr	12	90.50	13.11	73.00–117.00	86.50	81.25–99.75

IQR: Interquartile range; FMT: Fecal microbiota transplantation.

**Table 2 Glycated hemoglobin levels over the course of the study, by group**


Group	N	Mean	SD	Range	Median	IQR
FMT ( <i>n</i> = 15)						
Baseline	11	6.75	1.09	5.60–8.90	6.30	6.10–7.60
6 wk	11	6.65	1.09	5.60–9.10	6.10	6.00–7.60
6 mo	11	6.95	1.19	5.40–9.50	6.50	6.20–7.70
1 yr	11	7.34	1.85	5.60–11.50	6.70	5.80–8.30
Placebo ( <i>n</i> = 13)						
Baseline	11	6.99	1.99	4.80–12.50	6.60	6.00–7.50
6 wk	11	6.75	1.38	5.00–10.20	6.30	6.00–7.40
6 mo	11	6.97	1.98	4.90–12.20	6.40	5.90–7.20
1 yr	11	7.29	2.56	4.90–13.80	6.30	5.90–8.10

IQR: Interquartile range; FMT: Fecal microbiota transplantation.

randomized controlled trial[32], 38 obese male patients were randomized to receive autologous microbiota or allogeneic microbiota from lean donors. The authors found that, by six weeks after the procedures, there was a significant (11.5%) increase in insulin resistance among the patients who received allogeneic microbiota, although that increase was not maintained at 18 wk after the procedure, which suggests that FMT has only a short-term effect. In a double-blind randomized controlled study of FMT[33], 20 male patients with metabolic syndrome were allocated to receive autologous or allogeneic (vegan) microbiota. In that study, a slight improvement in insulin resistance was observed at two weeks after FMT in the patients receiving allogeneic microbiota.

In a systematic review of FMT in obese individuals with metabolic syndrome[34], the authors evaluated three randomized placebo-controlled studies involving a collective total of 63 patients. They identified no statistical differences between FMT and placebo in terms of the glycemic profile or weight loss. However, the studies evaluated differed in various aspects, including the number of donors, follow-up time, and means of preparation of the microbiota solution. Another systematic review of FMT in patients with obesity and metabolic syndrome[35], published in 2020, evaluated six studies: The three randomized placebo-controlled studies mentioned above[32,33] two randomized double-blind placebo-controlled studies[36] and the prepublication data of the present study. The authors of that review, which involved a collective total of 154 patients, detected no statistical difference between FMT and placebo in terms of the clinical parameters evaluated.

In the present study, there were no significant differences in biochemical or anthropometric parameters, between the two groups or at any of the time points evaluated. Nevertheless, there were




**Figure 1 Relative abundance of taxa.** A and B: Show the relative abundance of phyla and of the top 15 genera, respectively, in all samples at baseline, as well as in the placebo and fecal microbiota transplantation groups at 6 wk and 1 year after the procedures. FMT: Fecal microbiota transplantation.

significant postprocedural differences in the microbiota composition between the placebo group and the FMT group, as evidenced by the beta diversity results, which indicate that FMT is effective in changing the gut microbiome and that such changes can persist for at least one year after the procedure. However, other studies have shown that there is no difference in alpha diversity in the gut microbiome, as assessed with the Shannon diversity index, between patients receiving FMT and those receiving a placebo[33,34]. In one such study[33], the FMT group subjects were divided into two subgroups, based on the insulin sensitivity response observed: Metabolic responders and metabolic nonresponders. Among the metabolic responders, there was a significant increase (in relation to the baseline value) in the relative abundance of *Akkermansia muciniphila*. Human and animal studies have demonstrated that *A. muciniphila* is closely associated with improvements in insulin sensitivity[37]. Its beneficial effects may be due to a microbe-induced increase in the intestinal level of endocannabinoids and epithelial expression of Toll-like receptor two, which regulates gut barrier function and inflammation[37]. However, we observed no difference between our FMT group and our placebo group, in terms of the abundance of *A. muciniphila*, at six weeks or one year. The lack of a statistical difference regarding the abundance of *A. muciniphila* cannot be evaluated in isolation, as the health of the gut microbiome is defined in terms of diversity, stability, resistance, and resilience[38].

### Limitations

This trial has some limitations. As gut dysbiosis can be influenced by inflammation, diet, and environmental exposures[39], there was great variability among the individuals evaluated. This variability could be attributed, in part, to the fact that the recommended standardized diet was not followed. All of the patients evaluated were insulin resistant or had diabetes, and it is known that the use of medications such as metformin can change the diversity of the intestinal microbiota[40]. In addition, there is as yet no well-established protocol for preparing the donor intestinal microbiota. Although we followed the



**Figure 2 Alpha diversity indices, by group, over time.** A: The Shannon diversity index; B: The Chao1 richness estimate; C: The Simpson diversity index; D: The operational taxonomic units observed, over time, in the placebo and fecal microbiota transplantation groups. FMT: Fecal microbiota transplantation; OTUs: Operational taxonomic units.

protocol devised by van Nood *et al*[2], it was not possible to ensure that the anaerobic bacteria remained viable until the time of transplantation. The two species most strongly associated with metabolic health—*Faecalibacterium prausnitzii* and *A. muciniphila*—are both anaerobic[41,42]. An anaerobic microbiota preparation protocol may be necessary to increase bacterial viability and engraftment success of strict anaerobes in FMT[43]. It would thus be possible to transplant a greater diversity of microbiota and keep the composition of the microbiota solution as close as possible to that of the donor sample. Furthermore, we opted for infusion by colonoscopy, which is just one of the many possible routes of delivery of FMT, and success rates have been shown to vary depending on the route of delivery[44]. Further studies are needed in order to understand the dose and duration of therapy required to maximize the therapeutic effect of FMT, while optimizing patient tolerance and compliance [45]. Moreover, we included only one donor (a female) and our sample comprised only female patients, whereas most comparable studies in the literature have evaluated male patients. Sex is recognized as an important factor in a variety of common conditions, including autoimmune, metabolic, cardiovascular, and psychiatric disorders[46]. Finally, our analysis was also limited not only by the small size of our sample but also by the small number of studies of the topic in the literature and their small sample sizes. As this was a single-center study, our findings may not reflect the outcomes that can be expected across global populations.

## CONCLUSION

In the present study, there were no significant differences in biochemical or anthropometric parameters, between the two groups or at any of the time points evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group and the FMT group, as evidenced by the beta diversity results, which indicate that FMT is effective in changing the gut microbiome and that such changes can persist for at least 1 year after the procedure.




Figure 3 Beta diversity over time. PbO: Placebo; FMT: Fecal microbiota transplantation.

## ARTICLE HIGHLIGHTS

### Research background

The prevalence of metabolic syndrome parallels that of obesity and diabetes—up to 45% of the population worldwide. New therapeutic methods have emerged to join efforts in the fight against obesity and metabolic syndrome.

### Research motivation

To investigate new methods for the treatment of metabolic syndrome.

### Research objectives

Evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.

### Research methods

This was a randomized, single-blind, placebo-controlled clinical trial comparing FMT and a sham procedure in patients with metabolic syndrome. The trial was registered at ensaiosclinicos.gov.br (identifier: U1111-1223-6951).

### Research results

There was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.

### Research conclusions

There were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.

### Research perspectives

Studies with larger patient samples should be carried out in order to assess the potential effects of fecal microbiota transplantation on clinical parameters.



## FOOTNOTES

**Author contributions:** da Ponte Neto AM contributed to the conception and design of the study, analyzed and interpreted the data, drafted the article; revised the article for important intellectual content, and approved the final version; Clemente ACO analyzed and interpreted the data, revised the article for important intellectual content, and approved the final version; Rosa PW analyzed and interpreted the data, drafted the article, revised the article for important intellectual content, and approved the final version; Ribeiro IB contributed to the conception and design of the study, analyzed and interpreted the data, drafted the article; revised the article for important intellectual content, and approved the final version; Nunes GC analyzed and interpreted the data, revised the article for important intellectual content, and approved the final version; Moreira L analyzed and interpreted the data, and approved the final version; Sparvoli LG analyzed and interpreted the data, drafted the article, revised the article for important intellectual content, and approved the final version; Cortez R analyzed and interpreted the data, drafted the article, revised the article for important intellectual content, and approved the final version; Taddei CR analyzed and interpreted the data, drafted the article, revised the article for important intellectual content, and approved the final version; Mancini M analyzed and interpreted the data, drafted the article, revised the article for important intellectual content, and approved the final version; De Moura EGH: analyzed and interpreted the data, drafted the article, revised the article for important intellectual content, and approved the final version.

**Institutional review board statement:** The study was approved by the Research Ethics Committee of the University of São Paulo School of Medicine, Approval No. CAAE: 62319916.9.0000.0068.

**Clinical trial registration statement:** The trial was registered at ensaiosclinicos.gov.br (identifier: U1111-1223-6951).

**Informed consent statement:** All subjects agreed to participate in this study after informed consent and ethical permission was obtained.

**Conflict-of-interest statement:** All the authors declare that they have no conflicts of interest related to this manuscript.

**Data sharing statement:** No additional data are available.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Brazil

**ORCID number:** Alberto Machado da Ponte Neto 0000-0001-6652-9159; Aniele Cristine Ott Clemente 0000-0001-5775-6210; Paula Waki Rosa 0000-0002-8712-5548; Igor Braga Ribeiro 0000-0003-1844-8973; Mateus Pereira Funari 0000-0002-4828-9320; Gabriel Cairo Nunes 0000-0001-6761-0194; Luana Moreira 0000-0002-1765-9165; Luiz Gustavo Sparvoli 0000-0003-4244-6513; Ramon Cortez 0000-0003-2059-4726; Carla Romano Taddei 0000-0003-0869-0651; Márcio C Mancini 0000-0002-5518-2759; Eduardo Guimarães Hourneaux de Moura 0000-0003-1215-5731.

**S-Editor:** Liu JH

**L-Editor:** Webster JR

**P-Editor:** Ju JL

## REFERENCES

- Saklayen MG.** The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep* 2018; **20**: 12 [PMID: 29480368 DOI: 10.1007/s11906-018-0812-z]
- Alberti KG, Zimmet P, Shaw J.** Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006; **23**: 469-480 [PMID: 16681555 DOI: 10.1111/j.1464-5491.2006.01858.x]
- GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Årnlöv J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cerci K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Fürst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezegebu HB, Mirakhorimov EM,**



- Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med* 2017; **377**: 13-27 [PMID: 28604169 DOI: 10.1056/NEJMoa1614362]
- 4 Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. *JAMA* 2001; **286**: 2845-2848 [PMID: 11735760 DOI: 10.1001/jama.286.22.2845]
- 5 Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. *Curr Diab Rep* 2004; **4**: 63-68 [PMID: 14764282 DOI: 10.1007/s11892-004-0013-9]
- 6 Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. *Nutrition* 1997; **13**: 65; discussion 64, 66 [PMID: 9058458 DOI: 10.1016/s0899-9007(96)00380-2]
- 7 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; **365**: 1415-1428 [PMID: 15836891 DOI: 10.1016/S0140-6736(05)66378-7]
- 8 Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. *J Clin Endocrinol Metab* 2007; **92**: 399-404 [PMID: 17284640 DOI: 10.1210/jc.2006-0513]
- 9 Clarke JTR. The Metabolic Syndrome : Time for a. 2005; 28 [DOI: 10.1017/CBO9780511544682.005]
- 10 Dao MC, Everard A, Aron-Wisniewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L; MICRO-Obes Consortium, Dumas ME, Rizkalla SW, Doré J, Cani PD, Clément K. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* 2016; **65**: 426-436 [PMID: 26100928 DOI: 10.1136/gutjnl-2014-308778]
- 11 Druart C, Dewulf EM, Cani PD, Neyrinck AM, Thiessen JP, Delzenne NM. Gut microbial metabolites of polyunsaturated fatty acids correlate with specific fecal bacteria and serum markers of metabolic syndrome in obese women. *Lipids* 2014; **49**: 397-402 [PMID: 24473752 DOI: 10.1007/s11745-014-3881-z]
- 12 Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci USA* 2004; **101**: 15718-15723 [PMID: 15505215 DOI: 10.1073/pnas.0407076101]
- 13 Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013; **500**: 541-546 [PMID: 23985870 DOI: 10.1038/nature12506]
- 14 Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* 2005; **102**: 11070-11075 [PMID: 16033867 DOI: 10.1073/pnas.0504978102]
- 15 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013; **368**: 407-415 [PMID: 23323867 DOI: 10.1056/NEJMoa1205037]
- 16 Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Appl Environ Microbiol* 2013; **79**: 5112-5120 [PMID: 23793624 DOI: 10.1128/AEM.01043-13]
- 17 Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics* 2011; **27**: 2194-2200 [PMID: 21700674 DOI: 10.1093/bioinformatics/btr381]
- 18 Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* 2013; **41**: D590-D596 [PMID: 23193283 DOI: 10.1093/nar/gks1219]
- 19 Chao, A. (1984). Nonparametric Estimation of the Number of Classes in a Population. *Scand J Stat* **11**: 265-270 [DOI: 10.1080/10485250802018253]
- 20 Pylro VS, Roesch LF, Morais DK, Clark IM, Hirsch PR, Tótola MR. Data analysis for 16S microbial profiling from different benchtop sequencing platforms. *J Microbiol Methods* 2014; **107**: 30-37 [PMID: 25193439 DOI: 10.1016/j.mimet.2014.08.018]
- 21 Shannon CE. "A mathematical theory of communication". *The Bell System Technical Journal* 1948; **27**: 379-423 [DOI: 10.1002/j.1538-7305.1948.tb01338.x]
- 22 Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. *Appl Environ Microbiol* 2005; **71**: 8228-8235 [PMID: 16332807 DOI: 10.1128/AEM.71.12.8228-8235.2005]
- 23 Navas-Molina JA, Peralta-Sánchez JM, González A, McMurdie PJ, Vázquez-Baeza Y, Xu Z, Ursell LK, Lauber C, Zhou H, Song SJ, Huntley J, Ackermann GL, Berg-Lyons D, Holmes S, Caporaso JG, Knight R. Advancing our understanding of the human microbiome using QIIME. *Methods Enzymol* 2013; **531**: 371-444 [PMID: 24060131 DOI: 10.1016/B978-0-12-407863-5.00019-8]
- 24 Kittelson JM. A Review of: "Fundamentals of Biostatistics, 7th ed., by B. Rosner". *J Biopharm Stat* 2011; **859** [DOI: 10.1080/10543406.2011.592364]
- 25 Sasson AN, Ingram RJM, Zhang Z, Taylor LM, Ananthakrishnan AN, Kaplan GG, Ng SC, Ghosh S, Raman M. The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. *Lancet Gastroenterol Hepatol* 2021; **6**: 754-769 [PMID: 34270915 DOI: 10.1016/S2468-1253(21)00097-2]
- 26 Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol* 2018; **11**: 1-10 [PMID: 29285689 DOI: 10.1007/s12328-017-0813-5]
- 27 Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of *Clostridium difficile* in adults: a systematic review. *JAMA*

- 2015; **313**: 398-408 [PMID: [25626036](#) DOI: [10.1001/jama.2014.17103](#)]
- 28 **Shen NT**, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. *Gastroenterology* 2017; **152**: 1889-1900.e9 [PMID: [28192108](#) DOI: [10.1053/j.gastro.2017.02.003](#)]
  - 29 **Shah A**, Macdonald GA, Morrison M, Holtmann G. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptual Framework. *Am J Gastroenterol* 2020; **115**: 814-822 [PMID: [32250997](#) DOI: [10.14309/ajg.0000000000000604](#)]
  - 30 **Zhang Q**, Hu N. Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus. *Diabetes Metab Syndr Obes* 2020; **13**: 5003-5014 [PMID: [33364804](#) DOI: [10.2147/DMSO.S286430](#)]
  - 31 **Vrieze A**, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Strees ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2012; **143**: 913-6.e7 [PMID: [22728514](#) DOI: [10.1053/j.gastro.2012.06.031](#)]
  - 32 **Kootte RS**, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smidt H, Harms AC, Hankemeijer T, Bergman JJGHM, Romijn HA, Schaap FG, Olde Damink SWM, Ackermans MT, Dallinga-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Strees ESG, Groen AK, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* 2017; **26**: 611-619.e6 [PMID: [28978426](#) DOI: [10.1016/j.cmet.2017.09.008](#)]
  - 33 **Smits LP**, Kootte RS, Levin E, Prodan A, Fuentes S, Zoetendal EG, Wang Z, Levison BS, Cleophas MCP, Kemper EM, Dallinga-Thie GM, Groen AK, Joosten LAB, Netea MG, Strees ESG, de Vos WM, Hazen SL, Nieuwdorp M. Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. *J Am Heart Assoc* 2018; **7** [PMID: [29581220](#) DOI: [10.1161/JAHA.117.008342](#)]
  - 34 **Zhang Z**, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, Walter J, Madsen KL. Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review. *Nutrients* 2019; **11** [PMID: [31557953](#) DOI: [10.3390/nu11102291](#)]
  - 35 **Proença IM**, Allegretti JR, Bernardo WM, de Moura DTH, Ponte Neto AM, Matsubayashi CO, Flor MM, Kotinda APST, de Moura EGH. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. *Nutr Res* 2020; **83**: 1-14 [PMID: [32987284](#) DOI: [10.1016/j.nutres.2020.06.018](#)]
  - 36 **Allegretti JR**, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguéns Blanco J, Garcia-Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson C. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. *Clin Gastroenterol Hepatol* 2020; **18**: 855-863.e2 [PMID: [31301451](#) DOI: [10.1016/j.cgh.2019.07.006](#)]
  - 37 **Shin NR**, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 2014; **63**: 727-735 [PMID: [23804561](#) DOI: [10.1136/gutjnl-2012-303839](#)]
  - 38 **Plovier H**, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* 2017; **23**: 107-113 [PMID: [27892954](#) DOI: [10.1038/nm.4236](#)]
  - 39 **Lozupone CA**, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature* 2012; **489**: 220-230 [PMID: [22972295](#) DOI: [10.1038/nature11550](#)]
  - 40 **Forsslund K**, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Herczeg R, Costea PI, Kultima JR, Li J, Jørgensen T, Levenez F, Dore J; MetaHIT consortium, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature* 2015; **528**: 262-266 [PMID: [26633628](#) DOI: [10.1038/nature15766](#)]
  - 41 **Vallianou NG**, Stratigou T, Tsarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. *Hormones (Athens)* 2019; **18**: 141-144 [PMID: [30719628](#) DOI: [10.1007/s42000-019-00093-w](#)]
  - 42 **Reunanen J**, Kainulainen V, Huuskonen L, Ottman N, Belzer C, Huhtinen H, de Vos WM, Satokari R. Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer. *Appl Environ Microbiol* 2015; **81**: 3655-3662 [PMID: [25795669](#) DOI: [10.1128/AEM.04050-14](#)]
  - 43 **Costello SP**, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. *Aliment Pharmacol Ther* 2017; **46**: 213-224 [PMID: [28612983](#) DOI: [10.1111/apt.14173](#)]
  - 44 **Chu ND**, Smith MB, Perrotta AR, Kassam Z, Alm EJ. Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations. *PLoS One* 2017; **12**: e0170922 [PMID: [28125667](#) DOI: [10.1371/journal.pone.0170922](#)]
  - 45 **Cammarota G**, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. *J Clin Gastroenterol* 2014; **48**: 693-702 [PMID: [24440934](#) DOI: [10.1097/MCG.0000000000000046](#)]
  - 46 **Davidovics ZH**, Michail S, Nicholson MR, Kocielek LK, Pai N, Hansen R, Schwerdt T, Maspons A, Shamir R, Szajewska H, Thapar N, de Meij T, Mosca A, Vandenplas Y, Kahn SA, Kellermayer R; FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric

Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr* 2019; **68**: 130-143 [PMID: [30540704](#) DOI: [10.1097/MPG.0000000000002205](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

